We recently published a list of These 10 Stocks Were Wednesday’s Worst Performers. In this article, we are going to take a ...

RNA vaccine developer Moderna (MRNA) is sinking 9% after Goldman Sachs downgraded the shares to Neutral from Buy. Why Goldman ...

Researchers at Tel Aviv University have achieved a breakthrough in drug delivery: they have successfully transported lipid ...

Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...

The bill would implement a moratorium for a decade. “I am not against vaccination in any way,” the freshman lawmaker said.

Moderna Inc (MRNA) stock saw a modest uptick, ending the day at $38.5 which represents a slight increase of $2.61 or 7.27% from the prior close of $35.89. The stock opened at $36.35 and touched a low ...

Ethris GmbH, a leading biotechnology company pioneering next-generation RNA therapeutics and vaccines, today announced promising topline data from the completed Phase 1 clinical trial of its lead mRNA ...

Every time a shuttle docks with the International Space Station (ISS), a delicate dance unfolds between the shuttle's docking ...

Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product ...

Moderna (MRNA) closed the latest trading day at $41.66, indicating a +0.6% change from the previous session's end. The stock outperformed the S&P 500, which registered a daily loss of 1.46%. Elsewhere ...

Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an ...

Moderna is set to receive $590m in funding from the HHS to expedite the development of mRNA-based pandemic influenza vaccines ...